Medisun Precision Medicine Ltd. is a development stage company based in Majuro, the Republic of the Marshall Islands, focused on creating targeted therapies for neurological conditions, primarily in the United States. The company's key initiatives include the ACX-31 program, which aims to deliver the chemotherapy drug temozolomide in conjunction with BCNU directly to brain tumors. Additionally, Medisun is developing BranchPoint, a microinjection brain catheter designed for the precise delivery of therapeutics to complex brain areas. The company has entered into a collaboration agreement with DelMar Pharmaceuticals to advance the ACX-31 program and has a consulting agreement with Lim Development Group for the development and commercialization of the BranchPoint device. Formerly known as Accurexa, Inc., Medisun Precision Medicine Ltd. was established in 2012 and rebranded in June 2017.

Euronav is a leading owner-operator of modern large tankers, offering comprehensive shipping services. It operates a core fleet with an average age of less than 8 years and supplements it through opportunistic charters. Euronav's vessels serve both the spot and period markets, with most Very Large Crude Carriers (VLCCs) operated in pools. The company also offers Floating, Storage, and Offloading (FSO) vessel services. Fleet management is conducted by three wholly-owned subsidiaries, ensuring high-quality design, maintenance, and operation.

Founded in 2015, FJ Labs is a New York-based venture capital firm focusing on stage-agnostic investments in marketplaces and consumer-facing startups. Their investment range varies from $50,000 to $5,000,000, typically at seed or series A stages.